Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
TCBS Texas Community Bancshares Inc
UPC Universe Pharmaceuticals Inc
MHH Mastech Digital Inc
GCTK GlucoTrack Inc
KODK Eastman Kodak Co
FYBR Frontier Communications Parent Inc
TPNEF Cub Energy Inc
ECC Eagle Point Credit Co LLC
CPHI China Pharma Holdings Inc
Go

Health Care : Biotechnology |
Company profile

Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.

Closing Price
$6.15
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
60,939
0

Tesla, Rivian and Nio stock price targets cut on supply chain troubles, Shanghai shutdowns

8:34 am ET June 27, 2022 (MarketWatch)
Print

Mizuho analyst Vijay Rakesh became little less bullish on electric vehicle makers Tesla Inc. (TSLA), Rivian Automotive Inc. (RIVN) and China-based NIO Inc. (NIO) on Monday, citing the negative effects of continued COVID-19-related Shanghai shutdowns and supply chain constraints. Although Rakesh reiterated his buy ratings on all three EV makers, he cut his stock price targets on Tesla to $1,150 to $1,300, on Rivian to $70 from $80 and on NIO to $48 from $55. Rakesh also slashed his June quarter deliveries estimate to 232,000 from approximately 296,000 and his calendar-2022 estimate to 1.25 million from 1.40 million. June-quarter delivery estimates for Rivian were cut to 3,900 from 4,200 and for NIO to 23,000 from 24,000. The cuts didn't weigh on the companies' stocks in Monday's premarket, however, as Tesla rallied 1.9%, Rivian rose 1.5% and NIO tacked on 1.3%, while futures for the S&P 500 edged up 0.5%.

-Tomi Kilgore

	

(END) Dow Jones Newswires

June 27, 2022 08:34 ET (12:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.